Pathophysiology of saphenous vein graft failure: a brief overview of interventions
- PMID: 22321569
- DOI: 10.1016/j.coph.2012.01.001
Pathophysiology of saphenous vein graft failure: a brief overview of interventions
Abstract
Coronary artery bypass graft surgery (CABG) is widely used for the treatment of atheromatous stenosis of coronary arteries. However, as many as 50% of grafts fail within 10 years after CABG due to neointima (NI) formation, a process involving the proliferation of vascular smooth muscle cells (VSMCs) and superimposed atherogenesis. To date no therapeutic intervention has proved successful in treating late vein graft failure. However, several diverse approaches aimed at preventing neointimal formation have been devised which have yielded promising results. In this review, therefore, we will summarise the pathophysiology of vein graft disease and then briefly consider interventional approaches to prevent late vein graft failure which include surgical technique, conventional pharmacology, external sheaths, cytostatic drugs and gene transfer.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Towards the treatment of saphenous vein bypass graft failure--a perspective of the Bristol Heart Institute.Biorheology. 2002;39(3-4):491-9. Biorheology. 2002. PMID: 12122271 Review.
-
Perivascular administration of drugs and genes as a means of reducing vein graft failure.Curr Opin Pharmacol. 2012 Apr;12(2):203-16. doi: 10.1016/j.coph.2012.02.012. Epub 2012 Mar 23. Curr Opin Pharmacol. 2012. PMID: 22445655 Review.
-
External support in preventing vein graft failure.Asian Cardiovasc Thorac Ann. 2012 Oct;20(5):615-22. doi: 10.1177/0218492312456980. Asian Cardiovasc Thorac Ann. 2012. PMID: 23087319 Review.
-
Animal models for studying vein graft failure and therapeutic interventions.Curr Opin Pharmacol. 2012 Apr;12(2):121-6. doi: 10.1016/j.coph.2012.01.002. Epub 2012 Jan 24. Curr Opin Pharmacol. 2012. PMID: 22281067 Review.
-
Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions.Ann Surg. 2013 May;257(5):824-33. doi: 10.1097/SLA.0b013e318288c38d. Ann Surg. 2013. PMID: 23574989 Review.
Cited by
-
Plateletcrit. A platelet marker associated with saphenous vein graft disease.Herz. 2014 Feb;39(1):142-8. doi: 10.1007/s00059-013-3798-y. Epub 2013 Apr 12. Herz. 2014. PMID: 23575980
-
Mature Vascular Smooth Muscle Cells, but Not Endothelial Cells, Serve as the Major Cellular Source of Intimal Hyperplasia in Vein Grafts.Arterioscler Thromb Vasc Biol. 2020 Aug;40(8):1870-1890. doi: 10.1161/ATVBAHA.120.314465. Epub 2020 Jun 4. Arterioscler Thromb Vasc Biol. 2020. PMID: 32493169 Free PMC article.
-
Multilineage commitment of Sca-1+ cells in reshaping vein grafts.Theranostics. 2023 Apr 1;13(7):2154-2175. doi: 10.7150/thno.77735. eCollection 2023. Theranostics. 2023. PMID: 37153747 Free PMC article.
-
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.Curr Atheroscler Rep. 2013 Jul;15(7):340. doi: 10.1007/s11883-013-0340-x. Curr Atheroscler Rep. 2013. PMID: 23719923 Free PMC article. Review.
-
Mechanical Strain Induces Transcriptomic Reprogramming of Saphenous Vein Progenitors.Front Cardiovasc Med. 2022 May 27;9:884031. doi: 10.3389/fcvm.2022.884031. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35711359 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical